Eribulin for advanced breast cancer: a drug evaluation.

Article Details

Citation
Copy to clipboard

Shablak A

Eribulin for advanced breast cancer: a drug evaluation.

J Breast Cancer. 2013 Mar;16(1):12-5. doi: 10.4048/jbc.2013.16.1.12. Epub 2013 Mar 31.

PubMed ID
23593076 [ View in PubMed
]
Abstract

Eribulin is a synthetic microtubule dynamics inhibitor that was developed from a marine natural product halichondrin B. It exhibited in vitro and in vivo activities against a wide number of malignancies. A number of advanced phase trials showed improved survival following eribulin treatment in pretreated advanced breast cancer patients. This review provides an overview of the background to the therapeutic use of eribulin in oncology, including its pharmacology, pharmacokinetics, clinical efficacy, safety, and potential economic factors.

DrugBank Data that Cites this Article

Drugs